Thank you to the Japanese Government and METI for this excellent feature in Reuters highlighting Shinobi Therapeutics’ immune-evasive iPSC technology. We’re proud to advance to the clinic this year with scalable, cost-effective breakthrough cell therapies designed to reach all patients and markets worldwide. https://lnkd.in/gEzCTSDy
About us
Shinobi Therapeutics is developing a new class of hypoimmune CD8ab iPS-T cells for cancer and beyond by using immune evasion to unlock the full potential of iPSCs.
- Website
-
https://www.shinobitx.com
External link for Shinobi Therapeutics
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- South San Francisco, CA
- Type
- Privately Held
- Founded
- 2023
Locations
-
Primary
Get directions
South San Francisco, CA, US
-
Get directions
Kyoto, JP
Employees at Shinobi Therapeutics
Updates
-
Today, a new chapter in medicine begins. Not one, but two iPSC-based cell therapy products have been approved in Japan. This is more than a regulatory milestone. It is the starting line of an entirely new drug modality. Congratulations to Sumitomo Pharma Co., Ltd. (Racthera) and Cuorips Inc for trailblazing the path forward. And heartfelt congratulations to Shinya Yamanaka, whose discovery of induced pluripotent stem cells transformed what was once science fiction into clinical reality. For all invested in drug discovery and development, the signal is clear: the future of regenerative medicine is no longer theoretical. It’s here and the race has begun. https://lnkd.in/eQZ6RgVW
-
We recently met with the exceptional clinical investigators leading our NJA-001 and NJA-201 Phase 1 trials in Japan. NJA-001 is a multi-functional iPS T cell therapy for solid tumors, designed with cytokine armoring to enhance tumor killing and reshape the tumor microenvironment. NJA-201 is an iPS NK cell therapy engineered to balance potent B cell depletion with safety for younger autoimmune patients. Both leverage our immune evasion platform to enable persistence, redosing, and reduced reliance on lymphodepletion. Grateful to our investigators and AMED for their partnership. Two programs moving into the clinic that will advance our mission to deliver innovative, accessible cell therapies for patients who need better options.
-
-
Shinobi Therapeutics reposted this
Our ongoing collaboration with Panasonic is transforming the future of off-the-shelf iPS cell therapies through automated manufacturing. We met with Tatsuo Ogawa (CTO of Panasonic) and the incredibly talented project team last week at Panasonic’s HQ in Osaka, Japan to review how machine learning is being deployed to build a fully automated device that will manufacture our cell therapy products at unprecedented scale and cost. Amazing progress by an amazing team! Thanks so much Yoshihiro Owaki for hosting us at your beautiful new R&D facility.
-
-
Our ongoing collaboration with Panasonic is transforming the future of off-the-shelf iPS cell therapies through automated manufacturing. We met with Tatsuo Ogawa (CTO of Panasonic) and the incredibly talented project team last week at Panasonic’s HQ in Osaka, Japan to review how machine learning is being deployed to build a fully automated device that will manufacture our cell therapy products at unprecedented scale and cost. Amazing progress by an amazing team! Thanks so much Yoshihiro Owaki for hosting us at your beautiful new R&D facility.
-
-
We’re excited to transition into a clinical company in 2026 as we seek IND clearances for both NJA-001 and NJA-201. With unlimited editing potential, our clonal iPSC platform allows us to engineer multiple cytotoxic and immunotherapy molecules into a single precision-targeted drug product to treat solid tumor patients at scale. This is just the beginning. See you all at JPM! https://www.shinobitx.com
-
What do GLP-1, AMPK and CAR-T all have in common? Scientists just know when a drug target or mechanism is ‘for real’. The data always speaks for itself. During my time leading target discovery groups at Novartis and Merck, we took some risks with programs that were built on weak data and hypothesis. But a few mechanisms I worked on over the years truly stood out as the real deal. One was GLP-1. As a postdoc in Joel Habener’s lab at Massachusetts General Hospital (2000-2003), where he discovered GLP-1’s function, we knew even then that this peptide was a powerful therapeutic and the data consistently spoke for itself. Another was AMPK, the enzyme that mediates the cellular effects of exercise, with dynamite biology and enormous therapeutic potential. I led a team at Merck that developed small molecule AMPK activators and the data we generated still gets me excited. Finally, CAR-T cell therapy stands out as the ‘real deal’, yet today’s autologous one-and-done products are too expensive and though potentially curative reach too few patients around the world. BUT, what if CAR-T was as affordable as other biologics and also re-dosable for cancer or autoimmune disease patients who relapse? That’s the vision behind our work at Shinobi Therapeutics: off-the-shelf CAR-T cell therapies that are accessible, affordable, and scalable. An optimal version of the 'real deal' that fits today’s healthcare systems and patient’s needs.
-
Shinobi Therapeutics reposted this
The promise of CAR-T cell therapy to treat and even cure certain cancers and autoimmune diseases is unquestionable. But the barriers to their general use and global uptake relate to cost, scale and convenience. At Shinobi Therapeutics we are solving for these 'access' issues with our immune evasive iPSC-derived CAR-T cell therapies. We're developing a pipeline of off-the-shelf products that will enter the clinic in 2026. This week I will be presenting an update and data from our two lead programs, NJA-001 and NJA-201 at the ISSCR conference in Boston focused on "Accelerating PSC-Derived Cell Therapies: Starting with the End in Mind" https://lnkd.in/ec9ixQ5D
-
We’re excited to share that Laurent Fischer has been appointed as independent Director and Board Chair of Shinobi Therapeutics. Dr. Fischer has successfully developed multiple next generation therapies and achieved significant exits along the way. We welcome Laurent to the team as we progress our two lead programs NJA-001 and NJA-201 to the clinic in 2026. https://lnkd.in/eUv5wtaP
-
We're excited to present data at the SITC Annual Meeting on our iPSC derived T cell platform, a differentiated approach that may overcome conventional clinical and commercial barriers to cell therapy. See the abstract here: https://lnkd.in/eirVncTK
-